We are committed to working with healthcare professionals to ensure patients receive the best treatment and care.
The rapid change of pace in research and treatments for amyloidosis makes it vital that healthcare professionals have access to up-to-date information on best practices. We provide unique resources and tailored information for doctors, nurses and other clinicians.
We collaborate with amyloidosis experts from around the world to design educational tools that provide clinicians with easy access to the most current information on scientific and clinical advances to help achieve earlier diagnosis and therapeutic intervention.
Webinar: PYP Imaging for Diagnosing Transthyretin Cardiac Amyloidosis
In this comprehensive webinar, Dr. Mathew Maurer and Dr. Sabahat Bokhari from Columbia University, provide useful tips and guidance on how to avoid the pitfalls when using PYP imaging for diagnosing cardiac ATTR.
Physician Education & Tools
ARC Cardiac Amyloidosis Alert Card
This easy-to-use pocket card identifies “low voltage” EKGs in combination with ECHO images of increased ventricular mass, which are very...
ARC and the FDA will be hosting a virtual Scientific Workshop as part of the Amyloidosis Forum work on Novel Endpoint Development in AL amyloidosis.
Following the most recent Amyloidosis Forum held on October 15, 2020, several different organ-specific working groups have formed through the ARC/FDA public private partnership to facilitate the development of a composite or multidomain endpoint for AL amyloidosis. This Amyloidosis Forum meeting will bring together each of these organ-specific working groups along with independent and regulatory statisticians to discuss the output of each working group and potential components to a composite or multidomain endpoint in AL amyloidosis.
The Amyloidosis Forum is a Public Private Partnership between the Amyloidosis Research Consortium (ARC) and the Food and Drug Administration (FDA). The Amyloidosis Forum is focused on accelerating drug development in AL amyloidosis.